Myeloproliferative Disorders I (Neoplasm)

Dr. Ibrahim, A. Adam

Objectives

- Classify myeloproliferative disorders (neoplasm).
- discuss definition, pathophysiology, clinical features, laboratory findings and principles of treatment of chronic myeloid leukaemia
- Discuss definition, types, pathophysiology, clinical features, laboratory findings and diagnosis of polycythaemia Vera

Introduction

 Myeloproliferative Disorders (Neoplasm)

Clonal proliferations of pluripotent
hematopoietic stem cells or very early precursors
Maturation maintained
Increased numbers of predominantly mature,
normal-appearing cells
Variable predisposition to transform to acute
leukemia or myelofibrosis

Classification

- **□** Old FAB classification:
- Chronic myelogenous leukemia, *BCR-ABL1*+ (CML)
- Polycythemia vera (P. Vera)
- Essential thrombocythemia (ET)
- Primary myelofibrosis (PMF)
 - P. Vera, ET and PMF are sometimes grouped together as the "Philadelphianegative MPNs" or Non leukaemic MPNs
- Myeloproliferative Disorders (Neoplasm)

Disease

Predominant

Cells

O CML:

Granulocytes

o P. vera:

Erythrocytes

o ET:

Platelets

O PMF:

Fibroblasts (driven

by

megakaryocytes)

*There can be overlap between the MPNs

Chronic Myelogenous Leukemia

- □ 20% of all leukemias in U.S.
 - ☐ Increasing incidence with age:

Peak age 40- 60 years However: Occurs at all ages \square Men > Women (~1.4:1) CML: Pathophysiology CML: Molecular **Pathogenesis** \square ABL: Tyrosine kinase involved in cellcell signaling ☐ BCR-ABL fusion protein: More potent tyrosine kinase than normal ABL protein Philadelphia Chromosome (t9;22)**BCR-ABL** Rearrangement CML: Phases of Disease ☐ Chronic Phase ☐ Accelerated Phase

☐ Blast Crisis

CML Chronic Phase

- ☐ Most common stage at diagnosis
- ☐ Typically lasted ~3-4 years:
 - May last <1 year, or >15 years
- ☐ Eventually transforms into more aggressive phase:
 - Directly into blast crisis, or:
 - Accelerated phase, then blast crisis

•

CML Chronic Phase: Clinical features

- ☐ A symptomatic
- **□** Splenomegaly
- ☐ May have systemic or hypermetabolic symptoms:
 - o Fever, night sweats, weight loss
 - Hyperuricemia: gouty arthritis, renal stones

 CML: Blast Crisis \square Definition: $\geq 20\%$ blasts in blood and/or marrow ☐ Most have myeloid phenotype (resemble AML) ☐ Some may have lymphoid phenotype(resemble acute lymphoblastic leukemia) Investigations and **Diagnosis** CBC + PBF☐ Very high WBC ☐ All stages of granulocyte maturation: ☐ Basophilia invariably present ☐ Thrombocytosis common

*PBF is almost diagnostic

Investigations and Diagnosis

☐ Mild anemia common

Other tests to confirming the Diagnosis

☐ Presence of Ph and/or *BCR/ABL* rearrangement
☐ Bone Marrow ??

*Demonstration of Ph or BCR/ABL rearrangement is mandatory

Treatment

- ☐ Tyrosine kinase inhibitors (TKIs):
 - Gleevec (imatinib mesylate)
- ☐ Hydroxyurea
- ☐ Interferon-a
- ☐ Bone marrow (stem cell) transplant

Polycythaemia

Definition

Polycythemia: Increase in RBC mass (erythrocytosis)

- ➤ Increase in total RBC mass (absolute erythrocytosis [polycythemia]), or
- ➤ Decrease in plasma volume (*relative* erythrocytosis; "pseudopolycythemia")

Polycythaemia

- ☐ Primary polycythemia (poycthaemia vera):
 - Independent of erythropoietin
- ☐ Secondary polycythemia: erythropoietin driven
 - Physiologically appropriate = driven by hypoxemia
 - Physiologically inappropriate = increased erythropoietin due to renal cysts, tumors

Polycythaemia Vera

- ☐ Uncommon, but not *very* rare
- ☐ Slight male predominance
- ☐ Older age group: Majority of cases between 60 to 80
- ☐ Caucasians > African-Americans

• P. Vera: Pathogenesis

- ☐ Believed that <u>all</u> cases of P. vera related to mutation in <u>JAK2 gene</u>
- ☐ Low EPO level can be surrogate for JAK2 mutation

· P. Vera: Pathogenesis

P. Vera: Symptoms & Signs

☐ Increased blood viscosity:
(Headache, dizziness, tinnitus, visual disturbances,
dyspnea)
☐ Splenomegaly:
☐ Thrombotic complications
☐ Bleeding from mucous membranes or into skin
☐ Pruritis
☐ Hyperuricemia

• P. Vera: Symptoms & Signs

Ruddy'' skın:
Hepatomegaly
Hypertension:
Dilated or engorged
retinal vessels

P. Vera: Investigations

1.	CBC and PBF
	Hemoglobin to >18 g/dL
	RBC count: Commonly $> 7 \times 10^6 / \text{mL}$
	Hematocrit: Typically >60% for men, >55% for
	women
	Leukocytosis & thrombocytosis are common
-	Bone marrow:
3 <u>. </u>	Molecular test JAK mutation.
•	P. Vera: Diagnosis
	Hemoglobin >18.5 g/dL in men, >16.5 g/dL in women, or other evidence of increased RBC volume
	Presence of JAK2 V617F or other functionally similar mutation
	Bone marrow biopsy showing hypercellularity with trilineage growth
	Serum EPO level below reference range
•	P. Vera: Treatment
	Phlebotomy is cornerstone of treatment:
	 Controls red cell mass by inducing iron deficiency
	 May be only therapy required
	Others:
	- Hydroxyurea

- Radioactive phosphorous (³²P) no longer recommended.
- Interferon-a

Questions

Thank you